Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

References

• Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75:392–396.
   PubMed Web of Science ®Google Scholar
• Denosumab (Prolia). Denosumab treatment to increase bone mass in men with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Canadian Agency for Drugs and Technologies in Health; Ottawa, Canada. 2015.
   Google Scholar
• Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.
   PubMedGoogle Scholar
• Wells G,Chernoff J,Gilligan JP, et al. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos. Int. 2016;27:13–19.PMCID:PMC4715844
   Google Scholar
• Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis 1. Endocr Rev. 2000;21:115–137.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1.
   PubMed Web of Science ®Google Scholar
• Bell NH. RANK ligand and the regulation of skeletal remodeling. J Clin Invest. 2003;111:1120–1122.
   PubMed Web of Science ®Google Scholar
• Duong LT, Rodan GA. Regulation of osteoclast formation and function. Rev Endocr Metab Disord. 2001;2:95–104.
   PubMedGoogle Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831.
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese M, Lewiecki EM, et al. Six-year safety and efficacy data from denosumab phase 2 extension study. J Clin Densitom. 2010;13:131–132.
   Google Scholar
• McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24:227–235.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599–2607.
   PubMed Web of Science ®Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–161.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765.
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–2157.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Zheng J, Libanati C, et al. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response–based meta-analysis. J Clin Endocrinol Metab. 2014;99:3746–3755.
   PubMed Web of Science ®Google Scholar
• Zhang L, Pang Y, Shi Y, et al. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause. 2015;22:1021–1025.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Tsang JF, et al. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med. 2007;167:1641.
   PubMedGoogle Scholar
• Adminstration USF and D. Drugs@FDA: FDA approved drug products. 2008. [Cited 2017 Feb]. Available from: Www.Fda.Gov.Cder/Orange/Default.Htm.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. [Cited 2016 Dec]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:iii–x,1-173.
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org.
   Google Scholar
• Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.
   PubMed Web of Science ®Google Scholar
• Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48–54.
   PubMed Web of Science ®Google Scholar
• Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet. Gynecol. 2013;121:1291–1299.
   Google Scholar
• Ebina K, Hashimoto J, Kashii M, et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J. Bone Miner. Metab. 2017;35:91–98.
   Google Scholar
• Sánchez A, Brun LR, Salerni H, et al. Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos. 2016;2016:1–6.
   Google Scholar
• Brown JP, Bolognese MA, Ho P-R, et al. Denosumab significantly increases bone mineral density compared with ibandronate and risedronate in postmenopausal women previously treated with an oral bisphosphonate who are at higher risk for fracture. J Bone Miner Res. 2013;28.
   Web of Science ®Google Scholar
• Chu C-H, Yeh K-T, Chen I-H, et al. Effects of denosumab on bone mineral density and renal function in postmenopausal women transitioning from raloxifene. Tzu Chi Med J. 2015;27:159–163.
   Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (London, England). 2013;382:50–56.
   PubMed Web of Science ®Google Scholar
• Miller PD, Pannacciulli N, Wang C, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163–3170.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int. 2015;26:2521–2527.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386:1147–1155.
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto J, Kashii M, et al. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017;35:91–98.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Efstathiadou ZA, et al. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism. 2015;64:1291–1297.
   PubMed Web of Science ®Google Scholar
• de Boissieu P, Kanagaratnam L, Mahmoudi R, et al. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol. 2017;73:517–523.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.
   PubMed Web of Science ®Google Scholar
• Desai PA, Vyas PA, Lane JM. Atypical femoral fractures: a review of the literature. Curr Osteoporos Rep. 2013;11:179–187.
   PubMed Web of Science ®Google Scholar
• Diab DL, Watts NB. Denosumab in osteoporosis. Expert Opin Drug Saf. 2014;13:247–253.
   PubMed Web of Science ®Google Scholar
• Khan AA, Leslie WD, Lentle B, et al. Atypical femoral fractures: a teaching perspective. Can Assoc Radiol J. 2015;66:102–107.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Bmj. 2011;343:d4002.
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. Bone. 2014;58:126–135.
   PubMed Web of Science ®Google Scholar
• Netelenbos JC, Geusens PP, Ypma G, et al. Adherence and profile of non-persistence in patients treated for osteoporosis – a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int. 2011;22:1537–1546.
   PubMed Web of Science ®Google Scholar
• Clark EM, Gould VC, Tobias JH, et al. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study. Osteoporos Int. 2016;27:579–590.
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223–231.
   PubMed Web of Science ®Google Scholar
• Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26:2479–2489.
   PubMed Web of Science ®Google Scholar
• Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22:1725–1735.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Satram-Hoang S, Tang E-T, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23:317–326.
   PubMed Web of Science ®Google Scholar
• Pawlowska M, Bilezikian JP. Beyond DXA: advances in clinical applications of new bone imaging technology. Endocr Pract. 2016;22:990–998.
   PubMed Web of Science ®Google Scholar
• Cheung AM, Adachi JD, Hanley DA, et al. High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Curr Osteoporos Rep. 2013;11:136–146.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26:2773–2783.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–523.
   PubMed Web of Science ®Google Scholar